CTSO vs RJF · rev $18.5M vs rev $15.91B
Cytosorbents Crp (CTSO) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
Cytosorbents Crp (CTSO) is a medical devices company listed on US.
RJF (RJF) common stock.
Latest reported CTSO revenue for 2026-06-30 was $18.5M. Net income was -$9.5M. CTSO currently screens at market cap $28.8M.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
CTSO currently screens at market cap $28.8M. RJF currently screens at market cap $0.
Not investment advice. Open the CTSO and RJF stock pages for the full models.
Not investment advice.